CHIPP™
Chaotrope-induced protein precipitation & proteome profiling (CHIPP™) is a readily scalable, label-free assay for the study of drug: target interactions.
Receive your quote directly from the manufacturer.
This novel technology, developed in-house by the scientific team at Momentum Biotechnologies, leverages isothermal, reversible chemical denaturation of proteins to enable sensitive drug target identification under near-physiological conditions with proteome-wide readout (>8,000 proteins). Magnetic particle-based precipitation facilitates increased experimental throughput (96-well plate format) and is compatible with a wide range of downstream workflows.
This robust and automated approach is well-suited for use as a front-line validation assay for primary screening hits, enabling the systematic analysis of drugs and compounds in a fast and reliable way. CHIPP™ demonstrates a high success rate for target identification across a wide range of compounds, including allosteric inhibitors, molecular glues, PROTACs, and enzyme inhibitors.
Applications of CHIPP™ for drug discovery and development include:
- Target identification and deconvolution
- Affinity and selectivity profiling
- Target engagement
Additional applications to support degrader development include:
- Analysis of ternary complex formation
- Target and off-target profiling
Brochures
Mass spectrometry services for drug discovery and proteomics workflows
This resource outlines Momentum Biotechnologies’ portfolio of mass spectrometry‑based services that supports drug discovery and development, including affinity selection mass spectrometry (ASMS), covalent binding assays, proteomic and chemoproteomic services, functional screening, data products, and more.
Mass spectrometry capabilities support drug discovery and target identification
This resource outlines Momentum Biotechnologies’ capabilities in mass spectrometry‑based drug discovery, including screening, target identification and proteomics services. The portfolio integrates high‑throughput workflows, chemoproteomics platforms, and data products, to support the analysis of protein interactions, modifications, and abundance across research applications.
Scaling target deconvolution with CHIPP
This resource introduces CHIPP™, a mass spectrometry‑based approach for target identification and deconvolution in drug discovery. The technique uses chaotrope‑induced protein precipitation to assess changes in protein stability upon drug binding, enabling label‑free detection of drug–target interactions under near‑physiological conditions.
Designed for scalability and automation, CHIPP can be performed in high‑throughput formats, supporting the analysis of large compound libraries and integration into early discovery workflows. Discover how the method has been applied to study diverse modalities, including enzyme inhibitors and targeted degraders, offering a sensitive and efficient solution for proteome‑wide profiling and target confirmation.
Technologies for target identification, deconvolution, and selectivity profiling
Advances in drug discovery demand faster, deeper insight into target identification, deconvolution, and selectivity profiling. Traditional methods are often slow, costly, and limited in throughput, restricting their use to only a few candidate compounds and delaying confident decision‑making early in R&D.
Discover how next‑generation, automation‑ready chemoproteomic and mass‑spectrometry‑based technologies enable scalable, label‑free analysis with proteome‑wide readouts. Plus, learn how these approaches allow scientists to analyze hundreds of compounds efficiently, improve target confidence, and accelerate research progression.
Momentum Biotechnologies launches CHIPP, a novel high-throughput target deconvolution technology
Novel mass spectrometry based assay enables scalable, label free analysis of drug target interactions
